These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 30288116)

  • 21. Geographic variation of intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, and hepatocellular carcinoma in the United States.
    Altekruse SF; Petrick JL; Rolin AI; Cuccinelli JE; Zou Z; Tatalovich Z; McGlynn KA
    PLoS One; 2015; 10(3):e0120574. PubMed ID: 25837669
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Asbestos: a hidden player behind the cholangiocarcinoma increase? Findings from a case-control analysis.
    Brandi G; Di Girolamo S; Farioli A; de Rosa F; Curti S; Pinna AD; Ercolani G; Violante FS; Biasco G; Mattioli S
    Cancer Causes Control; 2013 May; 24(5):911-8. PubMed ID: 23408245
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Risk of hepatobiliary and pancreatic cancers after hepatitis C virus infection: A population-based study of U.S. veterans.
    El-Serag HB; Engels EA; Landgren O; Chiao E; Henderson L; Amaratunge HC; Giordano TP
    Hepatology; 2009 Jan; 49(1):116-23. PubMed ID: 19085911
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tumor Budding in Intrahepatic Cholangiocarcinoma: A Predictor of Postsurgery Outcomes.
    Tanaka M; Yamauchi N; Ushiku T; Shibahara J; Hayashi A; Misumi K; Yasunaga Y; Morikawa T; Kokudo T; Arita J; Sakamoto Y; Hasegawa K; Fukayama M
    Am J Surg Pathol; 2019 Sep; 43(9):1180-1190. PubMed ID: 31335353
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Radiological features and outcomes of combined hepatocellular-cholangiocarcinoma in patients undergoing surgical resection.
    Chi CT; Chau GY; Lee RC; Chen YY; Lei HJ; Hou MC; Chao Y; Huang YH
    J Formos Med Assoc; 2020 Jan; 119(1 Pt 1):125-133. PubMed ID: 30876788
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association between Repeated Praziquantel treatment and Papillary, and Intrahepatic Cholangiocarcinoma.
    Luvira V; Kamsa-Ard S; Kamsa-Ard S; Luvira V; Srisuk T; Pugkhem A; Pairojkul C; Bhudhisawasdi V
    Ann Hepatol; 2018 Aug; 17(5):802-809. PubMed ID: 30145559
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Risk factors for intrahepatic cholangiocarcinoma: association between metformin use and reduced cancer risk.
    Chaiteerakij R; Yang JD; Harmsen WS; Slettedahl SW; Mettler TA; Fredericksen ZS; Kim WR; Gores GJ; Roberts RO; Olson JE; Therneau TM; Roberts LR
    Hepatology; 2013 Feb; 57(2):648-55. PubMed ID: 23055147
    [TBL] [Abstract][Full Text] [Related]  

  • 28. HBV Infection Status and the Risk of Cholangiocarcinoma in Asia: A Meta-Analysis.
    Zhang H; Zhu B; Zhang H; Liang J; Zeng W
    Biomed Res Int; 2016; 2016():3417976. PubMed ID: 27999794
    [No Abstract]   [Full Text] [Related]  

  • 29. Smoking, alcohol consumption, and the risk of extrahepatic cholangiocarcinoma: a meta-analysis.
    Ye XH; Huai JP; Ding J; Chen YP; Sun XC
    World J Gastroenterol; 2013 Dec; 19(46):8780-8. PubMed ID: 24379600
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association between praziquantel treatment and cholangiocarcinoma: a hospital-based matched case-control study.
    Kamsa-Ard S; Luvira V; Pugkhem A; Luvira V; Thinkhamrop B; Suwanrungruang K; Bhudhisawasdi V
    BMC Cancer; 2015 Oct; 15():776. PubMed ID: 26496745
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Secular trends in the incidence of cholangiocarcinoma in the USA and the impact of misclassification.
    Tyson GL; Ilyas JA; Duan Z; Green LK; Younes M; El-Serag HB; Davila JA
    Dig Dis Sci; 2014 Dec; 59(12):3103-10. PubMed ID: 25204668
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Persistent status of metabolic syndrome and risk of cholangiocarcinoma: A Korean nationwide population-based cohort study.
    Park JH; Hong JY; Park YS; Kang G; Han K; Park JO
    Eur J Cancer; 2021 Sep; 155():97-105. PubMed ID: 34371446
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of risk factors for extrahepatic cholangiocarcinoma: ABO blood group, hepatitis B virus and their synergism.
    Zhou Y; Zhou Q; Lin Q; Chen R; Gong Y; Liu Y; Yu M; Zeng B; Li K; Chen R; Li Z
    Int J Cancer; 2013 Oct; 133(8):1867-75. PubMed ID: 23564396
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Beclin 1 deficiency correlated with lymph node metastasis, predicts a distinct outcome in intrahepatic and extrahepatic cholangiocarcinoma.
    Wang TT; Cao QH; Chen MY; Xia Q; Fan XJ; Ma XK; Lin Q; Jia CC; Dong M; Ruan DY; Lin ZX; Wen JY; Wei L; Li X; Chen ZH; Wang L; Wu XY; Wan XB
    PLoS One; 2013; 8(11):e80317. PubMed ID: 24303007
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Metabolic disorders and the risk of cholangiocarcinoma.
    Ghidini M; Ramai D; Facciorusso A; Singh J; Tai W; Rijavec E; Galassi B; Grossi F; Indini A
    Expert Rev Gastroenterol Hepatol; 2021 Sep; 15(9):999-1007. PubMed ID: 34423721
    [No Abstract]   [Full Text] [Related]  

  • 36. Skeletal muscle metastasis from extrahepatic cholangiocarcinoma: A case report and literature review.
    Qian H; Huang Z; Sun X; Ren P
    Front Surg; 2022; 9():922834. PubMed ID: 36034354
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular profiling of intrahepatic and extrahepatic cholangiocarcinoma using next generation sequencing.
    Putra J; de Abreu FB; Peterson JD; Pipas JM; Mody K; Amos CI; Tsongalis GJ; Suriawinata AA
    Exp Mol Pathol; 2015 Oct; 99(2):240-4. PubMed ID: 26189129
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Epidemiological survey of biomarkers of hepatitis virus in patients with extrahepatic cholangiocarcinomas.
    Qu Z; Cui N; Qin M; Wu X
    Asia Pac J Clin Oncol; 2012 Mar; 8(1):83-7. PubMed ID: 22369448
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Epidemiology, risk factors, and pathogenesis of cholangiocarcinoma.
    Khan SA; Toledano MB; Taylor-Robinson SD
    HPB (Oxford); 2008; 10(2):77-82. PubMed ID: 18773060
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Metabolic syndrome increases the risk of primary liver cancer in the United States: a study in the SEER-Medicare database.
    Welzel TM; Graubard BI; Zeuzem S; El-Serag HB; Davila JA; McGlynn KA
    Hepatology; 2011 Aug; 54(2):463-71. PubMed ID: 21538440
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.